Longboard PharmaceuticalsLBPH
Market Cap: $1.32B
About: Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Employees: 33
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
400% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 5 (+4) [Q2]
81% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 27
28% more capital invested
Capital invested by funds: $820M [Q1] → $1.05B (+$228M) [Q2]
5% less funds holding
Funds holding: 104 [Q1] → 99 (-5) [Q2]
13.25% less ownership
Funds ownership: 113.05% [Q1] → 99.8% (-13.25%) [Q2]
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
73% less call options, than puts
Call options by funds: $235K | Put options by funds: $878K
Research analyst outlook
16 Wall Street Analysts provided 1 year price targets over the past 3 months
16 analyst ratings
HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 41 / 131 met price target | 136%upside $80 | Buy Maintained | 18 Sept 2024 |
Wedbush Laura Chico 49% 1-year accuracy 36 / 74 met price target | 30%upside $44 | Outperform Maintained | 17 Sept 2024 |
Cantor Fitzgerald Josh Schimmer 67% 1-year accuracy 36 / 54 met price target | 165%upside $90 | Overweight Reiterated | 16 Sept 2024 |
Truist Securities Joon Lee 71% 1-year accuracy 29 / 41 met price target | 77%upside $60 | Buy Initiated | 10 Sept 2024 |
Evercore ISI Group Josh Schimmer 67% 1-year accuracy 36 / 54 met price target | 136%upside $80 | Outperform Maintained | 26 Aug 2024 |
Financial journalist opinion
Based on 7 articles about LBPH published over the past 30 days